Glivec leukaemia drug action

Videonummer 11930022
Glivec leukaemia drug binding to its target, the enzyme Bcr-Abl tyrosine kinase. This enzyme is produced by a genetic mutation, the swapping of parts of two chromosomes, leading to the formation of the oncogene (cancer-causing gene) Bcr-Abl, which produces a constantly-active version of normal Abl tyrosine kinase. This causes chronic myelogenous leukaemia (CML), a cancer of white blood cells. The drug Glivec (Imatinib) works by binding to the active site of the Bcr-Abl enzyme, producing a change in shape that prevents the enzyme from functioning. This causes the death of cancerous cells expressing the enzyme. Glivec, the first such tyrosine kinase inhibitor to be produced, is marketed by Novartis.
Lizenzart: Lizenzpflichtig
Credit: Science Photo Library / Andrade, Ramon / 3dciencia
Modell-Rechte: nicht erforderlich
Eigentums-Rechte: nicht erforderlich
Länge: 10 Sekunden
Seitenverhältnis: 16:9
Restrictions: -

Preise für dieses Video ab 100 €

Werblich (Einzelne Webseiten etc.) ab 100 €
Redaktionell (Einzelne Webseiten etc.) ab 175 €
Medien (TV Film, Serie, TV Doku etc.) ab 230 €

Keywords

;